Brenda J Weigel (Brenda Weigel)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 11

Top Topics

Randomized Controlled Trial

Acute Lymphoblastic Leukemia

Hematopoietic Stem Cell

Top Venues

JCO precision oncology

Cancer discovery

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Elliot Stieglitz, Alex G Lee, Steven P Angus, Christopher Davis, Donald A Barkauskas, David C Hall, Scott C Kogan, Julia Meyer, Steven D Rhodes, Sarah K Tasian, Xiaoling Xuei, Kevin Shannon, Mignon L Loh, Elizabeth Fox, Brenda J Weigel
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group. Cancer discovery (2024)
Kieuhoa T Vo, Amit J Sabnis, P Mickey Williams, Sinchita Roy-Chowdhuri, David R Patton, Brent Coffey, Joel M Reid, Jin Piao, Lauren Saguilig, Todd A Alonzo, Stacey L Berg, Alok I Jaju, Elizabeth Fox, Brenda J Weigel, Douglas S Hawkins, Margaret M Mooney, Naoko Takebe, James V Tricoli, Katherine A Janeway, Nita L Seibel, Donald Williams Parsons
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO precision oncology 8 (2024)
Kieuhoa T Vo, Amit J Sabnis, P Mickey Williams, Sinchita Roy-Chowdhuri, David R Patton, Brent Coffey, Joel M Reid, Jin Piao, Lauren Saguilig, Todd A Alonzo, Stacey L Berg, Alok I Jaju, Elizabeth Fox, Brenda J Weigel, Douglas S Hawkins, Margaret M Mooney, Naoko Takebe, James V Tricoli, Katherine A Janeway, Nita L Seibel, Donald Williams Parsons
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO precision oncology 8 (2024)
Elliot Stieglitz, Alex G Lee, Steven P Angus, Christopher Davis, Donald A Barkauskas, David C Hall, Scott C Kogan, Julia Meyer, Steven D Rhodes, Sarah K Tasian, Xiaoling Xuei, Kevin Shannon, Mignon L Loh, Elizabeth Fox, Brenda J Weigel
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group. Cancer discovery (2024)
Kieuhoa T Vo, Amit J Sabnis, P Mickey Williams, Sinchita Roy-Chowdhuri, David R Patton, Brent Coffey, Joel M Reid, Jin Piao, Lauren Saguilig, Todd A Alonzo, Stacey L Berg, Alok I Jaju, Elizabeth Fox, Brenda J Weigel, Douglas S Hawkins, Margaret M Mooney, Naoko Takebe, James V Tricoli, Katherine A Janeway, Nita L Seibel, Donald Williams Parsons
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO precision oncology 8 (2024)
Margaret E Macy, Rajen J Mody, Joel M Reid, Jin Piao, Lauren Saguilig, Todd A Alonzo, Stacey L Berg, Elizabeth Fox, Brenda J Weigel, Douglas S Hawkins, Margaret M Mooney, P Mickey Williams, David R Patton, Brent D Coffey, Sinchita Roy-Chowdhuri, Naoko Takebe, James V Tricoli, Katherine A Janeway, Nita L Seibel, Donald Williams Parsons
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I). JCO precision oncology 8 (2024)
Theodore W Laetsch, Kathleen Ludwig, P Mickey Williams, Sinchita Roy-Chowdhuri, David R Patton, Brent Coffey, Joel M Reid, Jin Piao, Lauren Saguilig, Todd A Alonzo, Stacey L Berg, Joyce Mhlanga, Elizabeth Fox, Brenda J Weigel, Douglas S Hawkins, Margaret M Mooney, Naoko Takebe, James V Tricoli, Katherine A Janeway, Nita L Seibel, Donald Williams Parsons
Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D. JCO precision oncology 8 (2024)
Elliot Stieglitz, Alex G Lee, Steven P Angus, Christopher Davis, Donald A Barkauskas, David C Hall, Scott C Kogan, Julia Meyer, Steven D Rhodes, Sarah K Tasian, Xiaoling Xuei, Kevin Shannon, Mignon L Loh, Elizabeth Fox, Brenda J Weigel
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group. Cancer discovery (2024)
Lucas Moreno, Steven G DuBois, Julia L Glade Bender, Audrey Mauguen, Nicholas Bird, Vickie Buenger, Michela Casanova, François Doz, Elizabeth Fox, Lia Gore, Douglas S Hawkins, Shai Izraeli, David T W Jones, Pamela R Kearns, Jan J Molenaar, Karsten Nysom, Stefan Pfister, Gregory H Reaman, Malcolm A Smith, Brenda J Weigel, Gilles Vassal, Christian Michel Zwaan, Xavier Paoletti, Alexia E Iasonos, Andrew D J Pearson
Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Kara L Davis, Elizabeth Fox, Emasenyie Isikwei, Joel M Reid, Xiaowei Liu, Charles G Minard, Stephan D Voss, Stacey L Berg, Brenda J Weigel, Crystal L Mackall
A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (23) (2022)
Leo Mascarenhas, Chitose Ogawa, Theodore W Laetsch, Brenda J Weigel, Michael W Bishop, Julie I Krystal, Scott C Borinstein, Emily K Slotkin, Jodi A Muscal, Pooja Hingorani, Donna E Levy, Gary Mo, Ashwin Shahir, Jennifer Wright, Steven G DuBois
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. Cancer medicine 10 (3) (2021)